NASDAQ:BTAI

BioXcel Therapeutics Stock Forecast, Price & News

$25.95
+0.36 (+1.41 %)
(As of 08/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.23
$26.34
50-Day Range
$24.23
$38.83
52-Week Range
$23.79
$67.74
Volume201,005 shs
Average Volume476,016 shs
Market Capitalization$639.20 million
P/E RatioN/A
Dividend YieldN/A
Beta1.07
30 days | 90 days | 365 days | Advanced Chart
Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


BioXcel Therapeutics logo

About BioXcel Therapeutics

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.45 out of 5 stars

Medical Sector

134th out of 2,226 stocks

Pharmaceutical Preparations Industry

68th out of 870 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

Is BioXcel Therapeutics a buy right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BioXcel Therapeutics stock.
View analyst ratings for BioXcel Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than BioXcel Therapeutics?

Wall Street analysts have given BioXcel Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but BioXcel Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for BioXcel Therapeutics
.

How can I listen to BioXcel Therapeutics' earnings call?

BioXcel Therapeutics will be holding an earnings conference call on Tuesday, August 10th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13721977".

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced its earnings results on Sunday, May, 9th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.89) by $0.19.
View BioXcel Therapeutics' earnings history
.

How has BioXcel Therapeutics' stock price been impacted by Coronavirus?

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BTAI stock has decreased by 12.0% and is now trading at $25.95.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BTAI?

10 analysts have issued twelve-month price targets for BioXcel Therapeutics' stock. Their forecasts range from $60.00 to $140.00. On average, they expect BioXcel Therapeutics' stock price to reach $102.00 in the next year. This suggests a possible upside of 293.1% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, & Director (Age 60, Pay $1.45M)
  • Dr. Krishnan Nandabalan, Chief Digital Officer ?& Director (Age 58, Pay $150k)
  • Mr. William P. Kane Jr., Exec. VP & Chief Commercial Officer (Age 59, Pay $589.85k)
  • Dr. Reina Benabou M.D., Ph.D., Sr. VP & Chief Devel. Officer (Age 57, Pay $452.47k)
  • Mr. Richard I. Steinhart MBA, Sr. VP & CFO (Age 64)
  • Dr. Frank D. Yocca Ph.D., Sr. VP & Chief Scientific Officer (Age 65)
  • Ms. Mary Coleman, VP of Investment Relations
  • Mr. Javier Rodriguez, Sr. VP, Chief Legal Officer & Corp. Sec. (Age 49)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 52)
  • Dr. Cedric Burg, VP and Head of Global Clinical Operations & Project Management

Who are some of BioXcel Therapeutics' key competitors?

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Alliancebernstein L.P. (3.83%), DAVENPORT & Co LLC (0.06%) and HighPoint Advisor Group LLC (0.05%). Company insiders that own BioXcel Therapeutics stock include Bioxcel Llc, Frank Yocca, Peter Mueller, Vimal Mehta and Vincent O'neill.
View institutional ownership trends for BioXcel Therapeutics
.

Which institutional investors are selling BioXcel Therapeutics stock?

BTAI stock was sold by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC, and HighPoint Advisor Group LLC. Company insiders that have sold BioXcel Therapeutics company stock in the last year include Bioxcel Llc, Frank Yocca, Vimal Mehta, and Vincent O'neill.
View insider buying and selling activity for BioXcel Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying BioXcel Therapeutics stock?

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P.. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, and Vimal Mehta.
View insider buying and selling activity for BioXcel Therapeutics
or or view top insider-buying stocks.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $25.95.

How much money does BioXcel Therapeutics make?

BioXcel Therapeutics has a market capitalization of $639.20 million. The company earns $-82,170,000.00 in net income (profit) each year or ($3.79) on an earnings per share basis.

How many employees does BioXcel Therapeutics have?

BioXcel Therapeutics employs 50 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

Where are BioXcel Therapeutics' headquarters?

BioXcel Therapeutics is headquartered at 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]


This page was last updated on 8/2/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.